A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Assessment of PD-L1 (programmed cell death 1 ligand 1) expression by immunohistochemical analysis has been used as a predictive diagnostic test to identify responders and guide treatment in trials of the PD-1 (programmed cell death 1) axis inhibitors. The definition of PD-L1 positive lacks standardization, and prediction of response by immunohistochemical analysis is additionally limited by the subjective nature of this technique. OBJECTIVE: To examine whether PD-L1 antibody reagents are interchangeable by quantitatively comparing the expression of the PD-L1 protein. DESIGN, SETTING, AND PARTICIPANTS: In this immunohistochemistry standardization study, 30 randomly selected cases of lung cancer resected from January 1, 2008, through December 31, 2009, were obtained from Yale Pathology Archives with a range of expression of PD-L1. To test for protein measurement, rather than clinical utility, a PD-L1 index tissue microarray, including cell line and tissue controls, was used. The results were then validated on a commercially available, genetically defined PD-L1 engineered cell line array with a range of controlled protein-expressing cell lines using 6 monoclonal antibodies (SP142, E1L3N, 9A11, SP263, 22c3, and 28-8). Protein levels were measured by quantitative immunofluorescence and quantitative chromogenic assessment. Data analysis was performed from September 2015 through May 2016. RESULTS: Concordance between 4 antibodies revealed regression for tumor tissue cores (R2 = 0.42-0.91) and cell line cores (R2 = 0.83-0.97) by quantitative immunofluorescence in the PD-L1 index tissue microarray. All 6 antibodies had high levels of concordance (R2 = 0.76-0.99) when using chromogenic staining in isogenic cell lines. CONCLUSIONS AND RELEVANCE: Because the antibodies are highly concordant, these results suggest that assays based on the use of these antibodies could yield concordant results. They further suggest that previously described differences in PD-L1 expression in tissue are independent of the antibody used and likely attributable to tumor heterogeneity, assay- or platform-specific variables, or other factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 1×
“Chromogenic IHC analysis was quantified using the Aperio PositivePixelCountbasedon the intensityofmembrane staining of respective PD-L1 antibodies using a modified HER2 algorithm.(11) A detailed description of these methods and immunostaining examples are included in eFigure 2 and eFigure 3 in the Supplement.”
MethodPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Although some PD-L1 antibodies have been rigorously validated in the published literature, including 28-8 and E1L3N, others are less documented, and specific epitope sequences remain proprietary.(7,8)”
BackgroundPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
McLaughlin, J., Han, G., Schalper, K. A., Carvajal-Hausdorf, D., Pelekanou, V., Rehman, J., Velcheti, V., Herbst, R., LoRusso, P., & Rimm, D. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3638 · Cited by 837
Self-citationProgrammed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755
Self-citation
Cited by
Rimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764
“interaction with the PD-L1 epitope, are most likely only subtly different, if at all.(16)Thus, the variation seen in our study is most likely a function of the recipe or protocol for each assay.”
BackgroundSelf-citationImplications of the tumor immune microenvironment for staging and therapeutics
Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A., Baras, A. S., Patel, S. S., Anders, R. A., Rimm, D. L., et al. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.156 · Cited by 358
Self-citationWang, F.-H., Wei, X.-L., Feng, J., Li, Q., Xu, N., Hu, X.-C., Liao, W., Jiang, Y., Lin, X.-Y., Zhang, Q.-Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02712 · Cited by 348
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Lantuejoul, S., Sound-Tsao, M., Cooper, W. A., Girard, N., Hirsch, F. R., Roden, A. C., Lopez-Rios, F., Jain, D., Chou, T.-Y., Motoi, N., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.107 · Cited by 332
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Perez-Johnston, R., Sawan, P., Beras, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.065 · Cited by 324
Liu, Y., Zugazagoitia, J., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1040 · Cited by 322
“In other works, the antibody has been shown to be equivalent to other cytoplasmic domain PD-L1 antibodies (19), even though the assay has proven to be of lower sensitivity (20, 21).”
BackgroundSelf-citationRatcliffe, M. J., Sharpe, A., Midha, A., Barker, C., Scott, M., Scorer, P., Al-Masri, H., Rebelatto, M. C., & Walker, J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2375 · Cited by 301
Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Lopez-Beltran, A., Cimadamore, A., Blanca, A., Massari, F., Vau, N., Scarpelli, M., Cheng, L., & Montironi, R. (2021) · Cancers · doi:10.3390/cancers13010131 · Cited by 279
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., Dubinett, S. M., Ferris, A., Gandhi, L., Garon, E. B., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0382-2 · Cited by 253
Self-citationThe cutting-edge progress of immune-checkpoint blockade in lung cancer
Zhou, F., Qiao, M., & Zhou, C. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00577-5 · Cited by 231
Villarroel-Espindola, F., Yu, X., Datar, I., Mani, N., Sanmamed, M., Velcheti, V., Syrigos, K., Toki, M., Zhao, H., Chen, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2542 · Cited by 215
Self-citationMulticenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy014 · Cited by 215
Metadata
- Authors
- Gaule, P., Smithy, J. W., Toki, M., Rehman, J., Patell-Socha, F., Cougot, D., Collin, P., Morrill, P., Neumeister, V., & Rimm, D. L.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-02-01
- Volume
- 3
- Issue
- 2
- Pages
- 256
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2509467148
- Cited by
- 201
- References
- 13
- FWCI
- 17.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.